2024-512175-12-00招募中1 期
A PHASE I STUDY OF THE CEACAM5 x CD47 ANTIBODY NILK-2401 AS SINGLE AGENT OR IN COMBINATION WITH ANTI-PD-1 ANTIBODY IN SOLID CANCERS
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- NovImmune SA
- 入组人数
- 50
- 试验地点
- 4
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Jose Saro
Scientific
NovImmune SA
研究点 (4)
Loading locations...
相似试验
招募中
1 期
A phase I study of the mesothelin x CD47 antibody NI-1801, as a single agent and in combination with Anti-PD-1 antibody, or with paclitaxel in solid cancers2024-517752-35-00NovImmune S.A.82
招募中
1 期
Phase I/II study of anti-CD7 Chimeric Antigen Receptor-Expressing T cells in pediatric patients/young adult affected by relapsed/refractory CD7+ T-cell Acute Lymphoblastic Leukemia/LymphomaRelapsed/refractory CD7+ T-cell Acute Lymphoblastic Leukemia/LymphomaMedDRA version: 21.1Level: LLTClassification code: 10066110Term: T-cell lymphoblastic leukemia acute Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10042971Term: T-cell lymphoma Class: 100000004864CTIS2023-508355-39-00Ospedale Pediatrico Bambino Gesu'26
招募中
不适用
A Phase I-II study of virus neutralizing antibodies against SARS-CoV-2. A focus on convalescent plasma and hyperimmune anti-SARS-CoV2 immunoglobulinesNL-OMON22629Erasmus MC104
进行中（未招募）
1 期
The ConvP COVig PKPD study: an investigation for the use of plasma or antibodies against the novel coronavirus (SARS-CoV-2)COVID-19 or protective effect against in B-cell depleted patients or vaccination non-respondersMedDRA version: 23.1Level: LLTClassification code 10084464Term: COVID-19 immunizationSystem Organ Class: 100000004865EUCTR2021-000864-32-NLErasmus MC104
已完成
不适用
Alemtuzumab, MabCampath® with 2-weekly CHOP chemotherapy for mature T-cell non-Hodgkin's lymphomaMature T-cell non-Hodgkin's lymphomaCancerOther and unspecified types of non-Hodgkin's lymphomaISRCTN52265296Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (Netherlands)20